Japan approves St. Jude Medical ’ s EnSite, TactiCath

St. Jude Medical (NYSE:STJ) said today it won Japanese MHLW approval for its EnSite Precision cardiac mapping system and its TactiCath irrigated ablation catheter. The Ensite cardiac mapping system is designed for use in ablation procedures to visualize and aid in catheter navigation in the heart, providing detailed anatomical models and maps, St. Jude said. The system is designed to aid in diagnosing arrhythmias, guiding therapy and providing expanded procedural options. The St. Paul, Minn.-based company’s TactiCath quartz irrigated ablation catheter is designed for ablation procedures to treat atrial fibrillation. St. Jude touted the device as being designed to allow for “more control” of force during ablation procedures to create “more effective lesions.” “Our new EnSite Precision cardiac mapping system was designed to give the physician a means to precisely navigate within the heart, provide higher density diagnostic data to better inform their diagnosis and allow them to use the tools that make sense for each individual patient and situation. The system’s intelligent automation tools enable faster, more accurate high-density maps with greater consistency across cases, which are important factors in addressing the needs of today’s EP labs,” clinical, medical & scientific affairs veep Dr. Srijoy Mahapatra said in a prepared statement. “I see the most significant impact of this technological platform in supporting ab...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiovascular Catheters Imaging Regulatory/Compliance St. Jude Medical Source Type: news